Drug
Las41008 Fumaderm
Las41008 Fumaderm: highest development phase Phase 1, developed by Almirall. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| LAS41008 120 mg / Fumaderm® 120 mg NCT02955693 | Phase 1 | Psoriasis |
Latest
No recent events.
Follow Las41008 Fumaderm on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.